<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Terenziani, Monica</style></author><author><style face="normal" font="default" size="100%">D'Angelo, Paolo</style></author><author><style face="normal" font="default" size="100%">Inserra, Alessandro</style></author><author><style face="normal" font="default" size="100%">Boldrini, Renata</style></author><author><style face="normal" font="default" size="100%">Bisogno, Gianni</style></author><author><style face="normal" font="default" size="100%">Babbo, Gian Luca</style></author><author><style face="normal" font="default" size="100%">Conte, Massimo</style></author><author><style face="normal" font="default" size="100%">Dall' Igna, Patrizia</style></author><author><style face="normal" font="default" size="100%">De Pasquale, Maria Debora</style></author><author><style face="normal" font="default" size="100%">Indolfi, Paolo</style></author><author><style face="normal" font="default" size="100%">Piva, Luigi</style></author><author><style face="normal" font="default" size="100%">Riccipetitoni, Giovanna</style></author><author><style face="normal" font="default" size="100%">Siracusa, Fortunato</style></author><author><style face="normal" font="default" size="100%">Spreafico, Filippo</style></author><author><style face="normal" font="default" size="100%">Tamaro, Paolo</style></author><author><style face="normal" font="default" size="100%">Cecchetto, Giovanni</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mature and immature teratoma: A report from the second Italian pediatric study.</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatr Blood Cancer</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Pediatr Blood Cancer</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Child</style></keyword><keyword><style  face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style  face="normal" font="default" size="100%">Italy</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Grading</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Recurrence, Local</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Staging</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms, Second Primary</style></keyword><keyword><style  face="normal" font="default" size="100%">Neuroblastoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style  face="normal" font="default" size="100%">Teratoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Testicular Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">62</style></volume><pages><style face="normal" font="default" size="100%">1202-8</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Teratomas demonstrate a benign clinical behavior, however they may recur with malignant components or as teratoma, and in a small group of patients prognosis could be fatal. After the first Italian study, we collected cases of teratoma, alongside the protocol for malignant germ cell tumors.&lt;/p&gt;&lt;p&gt;&lt;b&gt;PROCEDURE: &lt;/b&gt;Patients with teratoma were collected from 2004 to 2014. Teratomas were classified according to the WHO classifications, as mature and immature. Patients with pathological aFP and/or bHCG, and those with a malignant germ cell component were not included.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The study enrolled 219 patients (150 mature, 69 immature teratomas) with a median age at diagnosis of 42 months. The primary sites involved were: 118 gonadal and 101 extragonadal teratomas. Two females with ovarian teratoma had a positive family history. Complete and incomplete surgeries were performed in 85% and 9% of cases. Seventeen events occurred: six females had a second metachronous tumor (5 contralateral ovarian teratoma, 1 adrenal neuroblastoma) and 11 teratomas relapsed/progressed (3 mature, 8 immature teratomas). Two patients died, one of progressive immature teratoma and one of surgical complications. At a median follow up of 68 months, the event-free, relapse-free, and overall survival rates were 90.6%, 94.3%, 98.6%, respectively.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Teratomas show a good prognosis, especially the mature ones: surgery and follow-up remain the standard approach. Incomplete surgery in immature teratoma is the group at greatest risk of relapse. Bilateral ovarian tumors are a possibility, and the rare family predisposition to ovarian mature teratoma warrants further analyses.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/25631333?dopt=Abstract</style></custom1></record></records></xml>